Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jan 10;45(1):e2.
doi: 10.1038/emm.2013.2.

The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation

Eun-Jung Kim  1 , Nayoun Kim, Seok-Goo Cho
Affiliations
Review

The potential use of mesenchymal stem cells in hematopoietic stem cell transplantation

Eun-Jung Kim et al. Exp Mol Med. .

Abstract

In the last 10 years, mesenchymal stem cells (MSCs) have emerged as a therapeutic approach to regenerative medicine, cancer, autoimmune diseases, and many more due to their potential to differentiate into various tissues, to repair damaged tissues and organs, and also for their immunomodulatory properties. Findings in vitro and in vivo have demonstrated immune regulatory function of MSCs and have facilitated their application in clinical trials, such as those of autoimmune diseases and chronic inflammatory diseases. There has been an increasing interest in the role of MSCs in allogeneic hematopoietic stem cell transplantation (HSCT), including hematopoietic stem cell engraftment and the prevention and treatment of graft-versus-host disease (GVHD), and their therapeutic potential has been reported in numerous clinical trials. Although the safety of clinical application of MSCs is established, further modifications to improve their efficacy are required. In this review, we summarize advances in the potential use of MSCs in HSCT. In addition, we discuss their use in clinical trials of the treatment of GVHD following HSCT, the immunomodulatory capacity of MSCs, and their regenerative and therapeutic potential in the field of HSCT.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MSC-mediated therapies targeting for hematopoietic stem cell transplantation. The potential uses of MSCs include treatment of GVHD, facilitation of hematopcietic engraftment, induction of mixed chimerism and induction of the GVT effect. MSCs possess unique properties of immune modulation and tissue regeneration. ↓ : suppression; ↑: promotion. GVHD, graft-versus-host disease; GVT, graft-versus-tumor; HLA, human leukocyte antigen; IDO, indoleamine 2,3-dioxygenase; MSCs, mesenchymal stem cells; TGF-β, transforming growth factor-β.
See this image and copyright information in PMC

References

    1. Thomas ED, Lochte HL, Jr, Lu WC, Ferrebee JW. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. N Engl J Med. 1957;257:491–496. - PubMed
    1. Park BH, Biggar WD, Good RA. Minnesota experience in bone-marrow transplantation in man, 1968 to June 1973. Transplant Proc. 1974;6:379–383. - PubMed
    1. Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, et al. Bone-marrow transplantation (first of two parts) N Engl J Med. 1975;292:832–843. - PubMed
    1. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763. - PubMed
    1. Srinivasan R, Barrett J, Childs R. Allogeneic stem cell transplantation as immunotherapy for nonhematological cancers. Semin Oncol. 2004;31:47–55. - PubMed

Publication types

LinkOut - more resources